12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Phase III data

Top-line data from the double-blind, international Phase III PALACE-2 trial in about 500 patients showed that twice-daily 20 and 30 mg oral apremilast each met the primary endpoint of ACR20 response rate at week 16 vs. placebo. Celgene said patients in the apremilast arms maintained the ACR20 response through week 24. PALACE-2 enrolled patients with active psoriatic...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >